Sujata Tyagi Dayal insider trades: Emergent BioSolutions (EBS) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Sujata reports to the SEC
Open-market buys and sales
2 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | EBS | ↓ Sell10b5-1 | 13,761 | $8.40 | $116K | Direct | May 4, 2026 (3d) |
| Nov 7, 2025 | EBS | ↓ Sell10b5-1 | 8,552 | $10.00 | $86K | Direct | Nov 10, 2025 (3d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other EBS insiders
Open-market trades in the last 12 months
About Sujata Tyagi Dayal's insider trades
Sujata Tyagi Dayal is a director at Emergent BioSolutions (EBS). Since Nov 7, 2025, Sujata has reported no open-market purchases and 2 sales worth $201K on SEC Form 4. In the last 12 months: 2 sales ($201K).
2 sales (100% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.
Their filings also include grants and awards (6 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every EBS insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.